Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 386 participants.

Also called NCT03115112

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 386 participants (enrolled count) (from the registry)
Sponsor
  • Theracos Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03115112
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Hungary, Japan, Poland, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03115112. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-12 (actual); primary completion 2018-10-31 (actual). Results posted on 2021-06-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Bexagliflozin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo for sitagliptin
Intervention (Drug)
Placebo for bexagliflozin
Lead sponsor
Theracos (class: industry)

Record details

Record id
cardio:ct-nct03115112
Content hash
e2e8b4711a8980704d27f2e6b28e7421a3ff7cfd5b6095279857954fd58b9490